Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Retained Earnings (2019 - 2025)

Eton Pharmaceuticals' Retained Earnings history spans 7 years, with the latest figure at -$114.0 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 6.23% year-over-year to -$114.0 million; the TTM value through Sep 2025 reached -$114.0 million, down 6.23%, while the annual FY2024 figure was -$107.9 million, 3.67% down from the prior year.
  • Retained Earnings for Q3 2025 was -$114.0 million at Eton Pharmaceuticals, down from -$112.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$87.0 million in Q1 2021 and bottomed at -$114.0 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$104.0 million (2022), against an average of -$102.6 million.
  • The largest annual shift saw Retained Earnings fell 18.85% in 2021 before it grew 2.15% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$94.1 million in 2021, then decreased by 9.59% to -$103.1 million in 2022, then fell by 0.91% to -$104.1 million in 2023, then fell by 3.67% to -$107.9 million in 2024, then dropped by 5.64% to -$114.0 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Retained Earnings are -$114.0 million (Q3 2025), -$112.0 million (Q2 2025), and -$109.5 million (Q1 2025).